At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 35 enrolled
Drug / intervention
Sunitinib Malate +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Evaluation of SU11248 (Sunitinib Malate) (NSC #736511) in the Treatment of Persistent or Recurrent Clear Cell Ovarian Carcinoma
In Brief
A Phase 2 clinical trial evaluating Laboratory Biomarker Analysis and Sunitinib Malate for Ovarian Clear Cell Adenocarcinoma and Recurrent Ovarian Carcinoma. Completed, enrolled 35 participants across 97 sites in 2 countries.
Detailed Summary
This phase II trial studies the side effects of sunitinib malate and how well it works in treating patients with ovarian cancer that is persistent or has come back. Sunitinib malate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesSouth Korea, United States
CollaboratorsNRG Oncology
Timeline
Phase 2CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedSep 2009
Enrollment StartApr 2010
Primary CompletionMay 2014
Study CompletionFeb 2019
TodayJul 2026
First PostedSep 18, 2009
Enrollment StartApr 19, 2010
Primary CompletionMay 1, 2014
Study CompletionFeb 9, 2019
TodayJul 2, 2026
Enrollment to primary: 4.0 yearsPosted 16.8 years ago
Interventions
Laboratory Biomarker Analysisother
Correlative studies
Sunitinib Malatedrug
Given PO